Jasper Therapeutics- Warrants (24/09/2026) Debt to Equity

The latest debt-to-equity ratio for JSPRW is 0.19. That is above the sector sector average of 0.14. Investors often review this figure alongside Jasper Therapeutics- Warrants (24/09/2026)'s historical trend and sector peers before judging valuation or financial health.

Against its sector companies, JSPRW currently prints 0.19 for debt-to-equity ratio, while the sector average sits near 0.14. That is roughly 34.7% above the sector mean. Large gaps often invite a closer look at Jasper Therapeutics- Warrants (24/09/2026)'s growth, margins, and balance sheet.

A debt-to-equity ratio of 0.19 for Jasper Therapeutics- Warrants (24/09/2026) is not 'good' or 'bad' on its own. Compare it with the peer average (0.14) and with JSPRW's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting JSPRW's debt-to-equity ratio (0.19), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.